TrialJournal of translational medicine2020
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
Stephen T Ryan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this paperpooled itcites it